ASCENSION

CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION (UNAUDITED)

For the Three Months Ended September 30, 2021 and 2020

Consolidated Financial Statements and Supplementary Information

For the Three Months Ended September 30, 2021 and 2020

Contents

Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	9
Supplementary Information	
Schedule of Net Cost of Providing Care of Persons	
Living in Poverty and Other Community Benefit Programs	43

Consolidated Balance Sheets (unaudited)

(Dollars in Thousands)

	September 30, 2021	June 30, 2021
Assets		
Current assets:		
Cash and cash equivalents	\$ 684,177	\$ 670,022
Short-term investments	96,464	97,222
Accounts receivable	3,386,587	3,253,061
Inventories	530,564	534,263
Due from brokers (see Notes 5 and 6)	117,059	97,225
Estimated third-party payor settlements	277,528	208,630
Other (see Notes 5 and 6)	858,867	1,120,666
Total current assets	5,951,246	5,981,089
Long-term investments (see Notes 5 and 6)	26,587,908	26,768,323
Property and equipment, net	11,017,038	11,066,802
Other assets:		
Right-of-use assets - leases	1,309,420	1,313,370
Investment in unconsolidated entities	1,327,024	1,363,777
Capitalized software costs, net	517,131	525,824
Other (see Notes 5 and 6)	1,409,540	1,380,054
Total other assets	4,563,115	4,583,025
Total assets	\$48,119,307	\$ 48,399,239

Continued on next page.

Consolidated Balance Sheets (unaudited) (Dollars in Thousands)

	September 30, 2021	June 30, 2021
Liabilities and net assets		
Current liabilities:		
Current portion of long-term debt	\$ 92,681	\$ 92,406
Long-term debt subject to short-term remarketing arrangements*	627,390	627,390
Current portion of lease obligations	248,390	245,535
Accounts payable and accrued liabilities (see Notes 5 and 6)	2,777,632	3,028,487
Estimated third-party payor settlements	773,933	756,700
Due to brokers (see Notes 5 and 6)	640,348	219,503
Current portion of self-insurance liabilities	314,960	314,960
Current portion of Medicare advanced payments	1,277,017	1,271,737
Other	743,116	686,804
Total current liabilities	7,495,467	7,243,522
Noncurrent liabilities: Long-term debt (senior and subordinated) Lease obligations, less current portion Self-insurance liabilities Pension and other postretirement liabilities Medicare advanced payments Other (see Notes 5 and 6) Total noncurrent liabilities Total liabilities	6,795,008 1,091,856 793,254 873,348 244,432 1,738,629 11,536,527 19,031,994	6,805,332 1,097,255 760,043 965,579 512,380 1,738,913 11,879,502 19,123,024
Net assets: Without donor restrictions: Controlling interest Noncontrolling interests Total net assets without donor restrictions	25,846,020 2,486,213 28,332,233	25,705,637 2,726,836 28,432,473
Net assets with donor restrictions	755,080	843,742
Total het assets Total liabilities and net assets	29,087,313 \$48,119,307	\$ 48,399,239

^{*}Consists of variable rate demand bonds with put options that may be exercised at the option of the bondholders, with stated repayment installments through 2047, as well as certain serial mode bonds with scheduled remarketing/mandatory tender dates occurring prior to September 30, 2022. In the event that bonds are not remarketed upon the exercise of put options for the variable bonds or scheduled mandatory tender bonds, management would utilize other sources to access the necessary liquidity. Potential sources include a drawdown on the \$600 million lines of credit, issuing commercial paper, and liquidating investments.

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Operations and Changes in Net Assets (unaudited) (Dollars in Thousands)

	The three months ended September 30,		
		2021	2020
Operating revenue:			
Net patient service revenue	S	6,384,101	5,977,323
Other revenue		552,904	649,523
Total operating revenue		6,937,005	6,626,846
Operating expenses:			
Salaries and wages		2,828,716	2,648,420
Employee benefits		589,135	579,149
Purchased services		795,098	706,232
Professional fees		336,941	320,485
Supplies		1,054,029	984,196
Insurance		84,092	74,107
Interest		56,965	58,394
Provider tax		166,928	166,002
Depreciation and amortization		328,563	325,407
Other		683,502	642,449
Total operating expenses before nonrecurring gains (losses), net		6,923,969	6,504,841
Income from operations before self-insurance trust fund investment			
return and nonrecurring gains (losses), net		13,036	122,005
Self-insurance trust fund investment return		2,786	30,701
Income from recurring operations		15,822	152,706
Nonrecurring gains (losses), net		9,085	(9,221)
Income from operations		24,907	143,485
Nonoperating gains (losses):			
Investment return, net		33,365	1,316,733
Other		46,347	(149,514)
Total nonoperating gains, net		79,712	1,167,219
Excess of revenues and gains over expenses and losses		104,619	1,310,704
Less noncontrolling interests		24,217	132,021
Excess of revenues and gains over expenses and losses			
attributable to controlling interest		80,402	1,178,683

Continued on next page.

Consolidated Statements of Operations and Changes in Net Assets (unaudited) (Dollars in Thousands)

	The three months ended September 30,		
	2021	2020	
Net assets without donor restrictions, controlling interest:			
Excess of revenues and gains over expenses and losses	\$ 80,402 \$	1,178,683	
Transfers (to) from sponsors and other affiliates, net	(624)	1,030	
Net assets released from restrictions for property acquisitions	13,666	9,613	
Pension and other postretirement liability adjustments	37,654	40,222	
Change in unconsolidated entities' net assets	9,724	17,013	
Other	(439)	(980)	
Increase in net assets without donor restrictions, controlling interest	140,383	1,245,581	
Net assets without donor restrictions, noncontrolling interest:			
Excess of revenues and gains over expenses and losses	24,217	132,021	
Net (distributions) contributions of capital	(264,840)	60,597	
Membership interest changes, net		1	
(Decrease) increase in net assets without donor restrictions,			
noncontrolling interests	(240,623)	192,619	
Net assets with donor restrictions:			
Contributions and grants	20,469	22,349	
Investment return	3,581	27,265	
Net assets released from restrictions	(21,902)	(17,727)	
Other	(90,810)	(14,781)	
(Decrease) increase in net assets with donor restrictions	(88,662)	17,106	
(Decrease) increase in net assets	(188,902)	1,455,306	
Net assets, beginning of period	29,276,215	21,587,248	
Net assets, end of period	\$ 29,087,313 \$	23,042,554	

The accompanying notes are an integral part of the consolidated financial statements.

Consolidated Statements of Cash Flows (unaudited) (Dollars in Thousands)

September 30, 2020 Operating activities (Decrease) increase in net assets \$ (188,902) \$ 1,455,306 Adjustments to reconcile increase (decrease) in net assets to net cash provided by operating activities: 328,563 325,407 Amortization of bond premiums, discounts, and debt issuance costs (8,878) (9,240) Amortization of bond premiums, discounts, and debt issuance costs (8,878) (9,240) Pension and other postretirement liability adjustments (37,654) (40,222) Unrealized losses (gains) on unrestricted investments, net 770,831 (1,107,060) Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (75,772) (36,558) Gain on sale of assets, net (75,7772) (36,558) Impairment and nome curring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 74,997 (26,952) (Increase) decrease in:		The three months ended			
Operating activities Checrease increase in net assets Checrease increase in net assets Checrease increase Checrease Che		•			
Cocrease in net assets S (188,902) \$ 1,455,306	On south and attack to		2021	_	2020
Adjustments to reconcile increase (decrease) in net assets to net cash provided by operating activities: Depreciation and amortization Amortization of bond premiums, discounts, and debt issuance costs (3,878) (9,240) Pension and other postretirement liability adjustments (37,654) (40,222) Unrealized losses (gains) on unrestricted investments, net Change in fair value of interest rate swaps (3,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net Inpairment and nonrecurring expenses Inpairment and nonrecurring expenses Inpairment and nonrecurring expenses Inpairment and nonrecurring expenses Instributions (contributions), investment return and other Donor restricted distributions (contributions), investment return and other Donor restricted distributions (contributions), investment return and other Other Intraces decrease in: Short-term investments Forse Instributions Accounts receivable Investments classified as trading Other assets Increase (decrease) in: Accounts payable and accrued liabilities Estimated third-party payor settlements, net Other current liabilities Other current liabilities Self-insurance liabilities Other current liabilities Self-insurance liabilities Other noncurrent liabilities			(100.003)	ø	1 455 206
cash provided by operating activities: 328,563 325,407 Depreciation and amortization 328,563 325,407 Amortization of bond premiums, discounts, and debt issuance costs (8,878) (9,240) Pension and other postretirement liability adjustments (37,654) (40,222) Unrealized losses (gains) on unrestricted investments, net 770,831 (1,107,060) Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) <		3	(188,902)	Þ	1,455,300
Depreciation and amortization 328,563 325,407					
Amortization of bond premiums, discounts, and debt issuance costs (8,878) (9,240) Pension and other postretirement liability adjustments (37,654) (40,222) Unrealized losses (gains) on unrestricted investments, net 770,831 (1,107,060) Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) <tr< td=""><td></td><td></td><td></td><td></td><td>225 425</td></tr<>					225 425
Pension and other postretirement liability adjustments (37,654) (40,222) Unrealized losses (gains) on unrestricted investments, net 770,831 (1,107,060) Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (10,30) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other (Increase) decrease in: 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872)	-		-		
Unrealized losses (gains) on unrestricted investments, net Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses Inja57 Transfers to sponsor and other affiliates, net Donor restricted distributions (contributions), investment return and other Donor restricted distributions (contributions), investment return and other Distributions (contributions) of noncontrolling interest, net Short-term investments Total Accounts receivable Inventories and other current assets Investments classified as trading Other assets Investments (29,482) Increase (decrease) in: Accounts payable and accrued liabilities Estimated third-party payor settlements, net Other current liabilities Other current liabilities Self-insurance liabilities Self-insurance liabilities Other noncurrent liabilities (46,366) I14,594	• · · · · · · · · · · · · · · · · · · ·				
Change in fair value of interest rate swaps (8,210) (8,267) Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced paym					
Change in equity of unconsolidated entities (79,918) (65,867) Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,326) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other			_		
Gain on sale of assets, net (75,772) (36,558) Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 558 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (29,482) (31,872) Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 <	-				
Impairment and nonrecurring expenses 1,357 282 Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: Short-term investments 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (29,482) (31,872) Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 33,211 (13,267)			(79,918)		(65,867)
Transfers to sponsor and other affiliates, net 624 (1,030) Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Gain on sale of assets, net		(75,772)		(36,558)
Donor restricted distributions (contributions), investment return and other 74,997 (26,952) Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Impairment and nonrecurring expenses		1,357		282
Distributions (contributions) of noncontrolling interest, net 264,840 (60,597) (60,597) Other 1,133 56,892 (Increase) decrease in: 758 19,344 Short-term investments 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Transfers to sponsor and other affiliates, net		624		(1,030)
Other 1,133 56,892 (Increase) decrease in: 758 19,344 Short-term investments 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Donor restricted distributions (contributions), investment return and other		74,997		(26,952)
(Increase) decrease in: 758 19,344 Short-term investments 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Distributions (contributions) of noncontrolling interest, net		264,840		(60,597)
Short-term investments 758 19,344 Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Other		1,133		56,892
Accounts receivable (138,613) (243,951) Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	(Increase) decrease in:				
Inventories and other current assets (77,987) (56,194) Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Accounts payable and accrued liabilities (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Short-term investments		758		19,344
Due from brokers (19,834) (40,280) Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Accounts receivable		(138,613)		(243,951)
Investments classified as trading (517,826) (173,658) Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Accounts payable and accrued liabilities (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Inventories and other current assets		(77,987)		(56,194)
Other assets (29,482) (31,872) Increase (decrease) in: (219,117) (278,851) Accounts payable and accrued liabilities (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Due from brokers		(19,834)		(40,280)
Increase (decrease) in: Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Investments classified as trading		(517,826)		(173,658)
Accounts payable and accrued liabilities (219,117) (278,851) Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Other assets		(29,482)		(31,872)
Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Increase (decrease) in:				
Estimated third-party payor settlements, net (51,665) 6,931 Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	Accounts payable and accrued liabilities		(219,117)		(278,851)
Due to brokers 420,845 191,298 Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594					
Medicare advanced payments (262,668) - Other current liabilities 87,776 250,068 Self-insurance liabilities 33,211 (13,267) Other noncurrent liabilities (46,366) 114,594	• • • • • • • • • • • • • • • • • • • •				191,298
Other current liabilities87,776250,068Self-insurance liabilities33,211(13,267)Other noncurrent liabilities(46,366)114,594	Medicare advanced payments				-
Self-insurance liabilities33,211(13,267)Other noncurrent liabilities(46,366)114,594					250,068
Other noncurrent liabilities (46,366) 114,594					
	Other noncurrent liabilities		-		
		_			

Continued on next page.

Consolidated Statements of Cash Flows (unaudited) (Dollars in Thousands)

	The three months ended September 30,			
		2021		2020
Investing activities				
Property, equipment, and capitalized software additions, net	\$	(302,677)	\$	(396,326)
Proceeds from sale of property and equipment		7,599		1,035
Distributions from unconsolidated entities, net		115,888		8,187
Net proceeds from sale/acquisition of other assets		299,442		141,537
Net cash provided by (used in) investing activities		120,252		(245,567)
Financing activities				
Repayment of debt, including financing lease obligations		(1,575)		(50,038)
Increase in assets under bond indenture agreements		(31)		(15)
Transfers (to) from sponsors and other affiliates, net		(624)		1,030
Donor restricted (distributions) contributions, investment return, and other		(74,997)		26,952
(Distributions) contributions of noncontrolling interest, net		(264,840)		60,597
Net cash (used in) provided by financing activities		(342,067)		38,526
Net increase in cash, cash equivalents, and restricted cash		228		19,215
Cash, cash equivalents, and restricted cash at beginning of period		727,913		717,216
Cash, cash equivalents, and restricted cash at end of period	\$	728,141	\$	736,431
Cash and cash equivalents	s	684,177	\$	649,123
Restricted cash, included in long-term investments		43,964		87,308
Cash, cash equivalents, and restricted cash at end of period	\$	728,141	\$	736,431

The accompanying notes are an integral part of the consolidated financial statements.

Notes to Consolidated Financial Statements (unaudited) (Dollars in Thousands)

1. Organization and Mission

Organizational Structure

Ascension Health Alliance, d/b/a Ascension (Ascension), is a Missouri nonprofit corporation formed on September 13, 2011. Ascension is a Catholic national health system consisting primarily of nonprofit corporations that own and operate local healthcare facilities, or Ministry Markets, located in 19 states and the District of Columbia. Ascension also serves as the direct or indirect member or shareholder of various subsidiaries including, but not limited to:

- Ascension Care Management
- Ascension Risk Services
- AscensionConnect
- Ascension Foundation
- Ascension Global Mission
- Ascension Healthcare
- Ascension Holdings
- Ascension Leadership Academy
- Ascension Technologies
- Ascension Capital
 - o Ascension Investment Management (AIM)
 - o AV Holding Company
 - o Ascension Ventures (AV)
- The Resource Group
- Smart Health Solutions

Ascension is also the majority investor in Ascension Alpha Fund, LLC (Alpha Fund), a limited liability company organized in the state of Delaware, as discussed in the Pooled Investment Fund note. Ascension and its member organizations are hereafter referred to collectively as the System.

Sponsorship

Ascension is sponsored by Ascension Sponsor, a Public Juridic Person. The Participating Entities of Ascension Sponsor are the Daughters of Charity of St. Vincent de Paul, St. Louise Province; the Congregation of St. Joseph; the Congregation of the Sisters of St. Joseph of Carondelet; the Congregation of Alexian Brothers of the Immaculate Conception Province, Inc. – American Province; and the Sisters of the Sorrowful Mother of the Third Order of St. Francis of Assisi – US/Caribbean Province.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

1. Organization and Mission (continued)

Mission

The System directs its governance and management activities toward strong, vibrant, Catholic Ministries united in service and healing, and dedicates its resources to spiritually centered care which sustains and improves the health of the individuals and communities it serves. In accordance with the System's mission of service to those persons living in poverty and other vulnerable persons, each Ministry Market accepts patients regardless of their ability to pay. The System uses four categories to identify the resources utilized for the care of persons living in poverty and community benefit programs:

- Traditional charity care includes the cost of services provided to persons who cannot afford healthcare because of inadequate resources and/or who are uninsured or underinsured.
- Unpaid cost of public programs, excluding Medicare, represents the unpaid cost of services provided to persons covered by public programs for persons living in poverty and other vulnerable persons.
- Cost of other programs for persons living in poverty and other persons who are vulnerable.
- Unreimbursed costs of community benefit programs and services for the broader community, not solely for the persons living in poverty, including health promotion and education, health clinics and screenings, and medical research.

Discounts are provided to all uninsured and underinsured patients, including those with the means to pay. Discounts provided to those patients who did not qualify for financial assistance are not included in the cost of providing care of persons living in poverty and other community benefit programs. The cost of providing care to persons living in poverty and other community benefit programs is estimated by reducing charges forgone by a factor derived from the ratio of each entity's total operating expenses to the entity's billed charges for patient care. Certain costs such as graduate medical education and certain other activities are excluded from total operating expenses for purposes of this computation.

The amount of traditional charity care provided, determined on the basis of cost, was \$106,136 and \$137,878 for the three months ended September 30, 2021 and 2020, respectively. The amount of unpaid cost of public programs, cost of other programs for persons living in poverty and other vulnerable persons, and community benefit cost is reported in the accompanying supplementary information.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies

Principles of Consolidation

The System consolidates all corporations and other entities for which operating control is exercised by the System or one of its member corporations, and all significant inter-entity transactions have been eliminated in consolidation. Excluding investments where the fair value option is elected, investments in entities where the System does not have operating control are recorded under the equity method of accounting, and results of operations are included in other operating revenue.

Use of Estimates

Management has made estimates and assumptions that affect the reported amounts of certain assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Carrying values of financial instruments classified as current assets and current liabilities approximate fair value. The fair values of financial instruments measured at fair value are disclosed in the Fair Value Measurements note.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and interest-bearing deposits with original maturities of three months or less.

Short-Term Investments

Short-term investments consist of investments with original maturities exceeding three months and up to one year.

Inventories

Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or market value using first-in, first-out (FIFO) or a methodology that closely approximates FIFO.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Long-Term Investments and Investment Return

Investments, excluding investments in unconsolidated entities accounted for under the equity method of accounting, are measured at fair value, are classified as trading securities, and include pooled short-term investment funds; U.S. government, state, municipal and agency obligations; corporate and foreign fixed income securities; asset-backed securities; and equity securities. Investments also include alternative investments and other investments which are valued based on the net asset value of the investments, as further discussed in the Fair Value Measurements note. As discussed in the Pooled Investment Fund note, the Alpha Fund also holds derivative investments, which are measured at fair value.

Long-term investments include assets limited as to use of \$1,627,493 and \$1,560,296 at September 30, 2021 and June 30, 2021, respectively, and are comprised primarily of investments placed in trust, donor restricted cash and cash equivalents, and investments held by captive insurance companies for the payment of self-insured claims.

Purchases and sales of investments are accounted for on a trade-date basis. Investment returns consist of dividends, interest, and gains and losses. The cost of substantially all securities sold is based on the FIFO method. Investment returns, excluding returns of self-insurance trust funds, are reported as nonoperating gains (losses) in the Consolidated Statements of Operations and Changes in Net Assets, unless the return is restricted by donor or law. Investment returns of self-insurance trust funds are reported as a separate component of income from operations in the Consolidated Statements of Operations and Changes in Net Assets.

Property and Equipment

Property and equipment are stated at cost or, if donated, at fair market value at the date of the gift. Depreciation is determined on a straight-line basis over the estimated useful lives of the related assets. The range of estimated useful lives used in computing depreciation is as follows: buildings and leasehold improvements, 2 to 40 years; and equipment, 2 to 20 years. Depreciation expense for the three months ended September 30, 2021 and 2020 was approximately \$276,000 and \$269,000, respectively.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

A summary of property and equipment is as follows:

	September 30, 2021	June 30, 2021
Land and improvements	\$ 1,392,096	\$ 1,372,957
Buildings and equipment	21,523,706	21,327,952
	22,915,802	22,700,909
Less accumulated depreciation	12,404,930	12,138,572
	10,510,872	10,562,337
Construction in progress	506,166	504,465
Total property and equipment, net	\$ 11,017,038	\$ 11,066,802

Several capital projects have remaining construction and related equipment purchase commitments of approximately \$656,000 as of September 30, 2021.

Intangible Assets

Intangible assets primarily consist of goodwill and capitalized computer software costs, including internally developed software. Costs incurred in the development and installation of internal use software are expensed or capitalized depending on whether they are incurred in the preliminary project stage, application development stage, or post-implementation stage, and the nature of the costs. Intangible assets are included in the Consolidated Balance Sheets as presented in the table that follows.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Capitalized software costs in the following table include software in progress of \$107,722 and \$103,977 at September 30, 2021 and June 30, 2021, respectively:

	Se	September 30, 2021		• ,		• ,		
Capitalized software costs	\$	2,496,546	\$	2,473,145				
Less accumulated amortization		1,979,415		1,947,321				
Capitalized software costs, net		517,131		525,824				
Goodwill		356,834		356,726				
Other, net		36,716		37,308				
Intangible assets included in other assets		393,550		394,034				
Total intangible assets, net	\$	910,681	\$	919,858				

Intangible assets whose lives are indefinite, primarily goodwill, are not amortized and are evaluated for impairment at least annually or when circumstances indicate a possible impairment may exist. Intangible assets with definite lives, primarily capitalized computer software costs, are amortized over their expected useful lives. Amortization expense for these intangible assets for the three months ended September 30, 2021 and 2020 was approximately \$53,000 and \$56,000, respectively.

Asset Impairment

Long-lived assets, intangible assets, and joint ventures are reviewed for impairment whenever events or business conditions indicate the carrying amount of such assets may not be fully recoverable. Initial assessments of recoverability are based on estimates of undiscounted future net cash flows associated with an asset or group of assets. Where impairment is indicated, the carrying amount of an asset or group of assets is reduced to fair value based on future discounted net cash flows or other estimates of fair value.

Noncontrolling Interests

The Consolidated Financial Statements include all assets, liabilities, revenues, and expenses of entities that are controlled and consolidated by the System. Noncontrolling interests in the Consolidated Balance Sheets represent the portion of net assets owned by entities outside the System, for those entities in which the System's ownership interest is less than 100%.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Net Assets

Net Assets Without Donor Restrictions

Net assets without donor restrictions are those whose use by the System has not been limited by donors and are available for general operating use.

Net Assets With Donor Restrictions

Net assets with donor restrictions include those whose use by the System has been limited by donors for a specific time period or purpose, primarily for patient care, operations, and property and equipment.

This category also includes net assets restricted by donors to be maintained in perpetuity. The income generated from these restricted investments is primarily used to purchase equipment and to provide charity care and other health and educational services. Contributions with donor-imposed restrictions that are met in the same reporting period are reported as net assets without donor restrictions.

Performance Indicator

The performance indicator is the excess of revenues and gains over expenses and losses. Pension and other postretirement liability adjustments, transfers to or from sponsors and other affiliates, net assets released from restrictions for property acquisitions, and changes in unconsolidated entities' net assets are not included in the performance indicator.

Operating and Nonoperating Activities

The System's primary mission is to meet the healthcare needs in its communities served through a broad range of general and specialized healthcare services, including inpatient acute care, outpatient services, long-term care, and other healthcare services. Activities directly associated with the furtherance of this purpose are considered to be operating activities. Other activities that result in gains or losses peripheral to the System's primary mission are considered to be nonoperating.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Net Patient Service Revenue and Accounts Receivable

Net patient service revenue relates to contracts with patients, and in most cases involve a third-party payor (Medicare, Medicaid, commercial and other managed care insurance companies) in which the System's performance obligations are to provide health care services. Net patient service revenues are recorded at expected collectible amounts over the time in which obligations to provide health care services are satisfied. Revenue is accrued to estimate the amount of revenue earned to date for patients who have not been discharged and whose care services are not complete as of the reporting period. Substantially all the System's performance obligations are satisfied in one year.

The transaction price is determined based on gross charges for services provided, reduced by contractual adjustments provided to third-party payers, discounts provided to uninsured patients in accordance with the System's charity care policy, and implicit price concessions provided primarily to uninsured patients. Patients who have health care insurance may also have discounts applied related to their copayment or deductible. Implicit price concessions are recorded as a direct reduction to net patient service revenue and are based primarily on historical collection experience.

Estimates of contractual adjustments and discounts are determined by major payor classes for inpatient and outpatient revenues based on contractual agreements, discount policies and historical experience. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and frequent changes in commercial and managed care contractual terms resulting from contract renegotiations and renewals.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Adjustments to revenue related to prior periods increased net patient service revenue by \$20,648 and \$10,218 for the three months ended September 30, 2021 and 2020, respectively.

Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. Such estimates are determined through either a probability-weighted estimate or an estimate of the most likely amount, depending on the circumstances related to a given estimated settlement item.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews and investigations.

Net patient service revenue earned for the three months ended September 30, 2021 and 2020, is as follows:

	The	The three months ended September 30,				
	2021			2020		
Inpatient care	\$	3,083,497	\$	2,853,946		
Ambulatory care		2,472,198		2,310,533		
Physician practices		728,653		695,249		
Long-term care		99,753		117,595		
Total net patient service revenue	\$	6,384,101	\$	5,977,323		

The System grants credit without collateral to its patients. Net patient service revenues earned by payor and significant concentrations of accounts receivable are as follows:

	Net Patient Service Revenue The three months ended		Accounts Receivable			
	September 30,		September 30,	June 30,		
	2021	2020	2021	2021		
Medicare - traditional and managed	34.8 %	36.6 %	28.5 %	30.3 %		
Medicaid - traditional and managed	13.7	12.9	10.0	9.8		
Other commercial and managed care	44.4	42.6	47.4	46.0		
Self-Pay and other	7.1	7.9	14.1	13.9		
	100.0 %	100.0 %	100.0 %	100.0 %		

Deductibles, copayments, and coinsurance under third-party payment programs which are the patient's responsibility are included within the primary payor category in the preceding table.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient deductibles and copayments remain outstanding.

Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management's assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators

Management relies on the results of detailed reviews of historical write-offs and collections of revenues and accounts receivable as a primary source of information in estimating the collectability of accounts receivable. Management updates the hindsight analysis at least quarterly, using primarily a rolling twelve-month collection history and write-off data. These routine, quarterly changes in estimates have not resulted in material adjustments to the valuations of accounts receivable or period-to-period comparisons of results of operations.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Other Operating Revenue

Other operating revenues are recorded at amounts the System expects to collect in exchange for providing goods or services not directly associated with patient care and recorded over the time in which obligations to provide goods or services are satisfied. The amounts recognized reflect consideration due from customers, third party payors, and others. Components of other operating revenue are included in the following table for the three months ended September 30, 2021 and 2020:

	The three months ended September 2021 2020			•
Cafeteria and vending	\$	15,066	\$	13,053
Provider Relief Funds (see Note 3)		4,014		184,849
Contracted services		50,017		52,378
Donations and grants		20,214		20,081
Gains on asset sales		78,130		36,928
Insurance plans		22,326		17,985
Joint venture income		70,145		57,789
Lab services		20,964		20,832
Lease and rental income		21,443		21,162
Retail pharmacy		137,784		116,223
Supplemental care programs		77,615		68,233
Other		35,186		40,010
Total other revenue	\$	552,904	\$	649,523

Supplemental care is revenue related to expansion and improvement of care through programs including accountable care organizations, shared savings, and other similar arrangements. Contracted services primarily include revenue from services provided under third party arrangements.

Nonrecurring Gains (Losses), Net

Nonrecurring gains (losses) are primarily related to natural disasters and related insurance proceeds and other recoveries.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Amortization

Bond issuance costs, discounts, and premiums are amortized over the term of the bonds or the fixed interest period, if applicable, primarily using a method approximating the effective interest method.

Capitalized software, including internally developed software, is amortized on a straight-line basis over the expected useful life of the software.

Income Taxes

The member healthcare entities of the System are primarily tax-exempt organizations under Internal Revenue Code Section 501(c)(3) or Section 501(c)(2), and their related income is exempt from federal income tax under Section 501(a). The System accounts for uncertainty in income tax positions by applying a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The System has determined that no material unrecognized tax benefits or liabilities exist as of September 30, 2021.

Regulatory Compliance

Ascension periodically undergoes investigations or audits by federal, state and local agencies involving compliance with a variety of laws and regulations. These investigations seek to determine compliance with, among other things, laws and regulations relating to Medicare and Medicaid reimbursement, including billing practice for certain services.

While no assurance can be given concerning the outcome of any current investigation, management believes that adequate reserves have been established, when available information indicates that a loss is probable and the range of loss can be reasonably estimated, and the outcome of any current investigations will not have a material effect on the Consolidated Financial Statements of the System.

Reclassifications

Certain reclassifications were made to the September 30, 2020 Consolidated Financial Statements to conform to the September 30, 2021 presentation.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Subsequent Events

The System evaluates the impact of subsequent events, which are events that occur after the Consolidated Balance Sheet date, but before the Consolidated Financial Statements are issued, for potential recognition or disclosure in the Consolidated Financial Statements as of the Consolidated Balance Sheet date. For the three months ended September 30, 2021, the System evaluated subsequent events through November 19, 2021, representing the date on which the Consolidated Financial Statements were issued.

In October 2021, Ascension and Adventist Health System Sunbelt Healthcare Corporation, d/b/a AdventHealth, decided to unwind their AMITA Health partnership, the joint operating company serving patients in the greater Chicago, Illinois area. After the partnership dissolution is completed, Ascension will operate its Illinois facilities separately from AdventHealth and continue to serve healthcare needs in the greater Chicago area.

3. COVID-19 Pandemic and CARES Act Funding

On March 11, 2020, the World Health Organization designated the COVID-19 outbreak as a global pandemic. In response to COVID-19, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, was signed into law on March 27, 2020. The CARES Act authorizes funding to hospitals and other healthcare providers to be distributed through the Public Health and Social Services Emergency Fund (Provider Relief Fund).

Payments from the Provider Relief Fund are to be used to prevent, prepare for, and respond to coronavirus, and shall reimburse the recipient for health care related expenses and lost revenues attributable to coronavirus. Additionally, funds are available to reimburse providers for COVID-19 related treatment of uninsured patients.

For the three months ended September 30, 2021 and 2020, the System recognized revenue associated with Provider Relief Fund payments of \$4,014 and \$184,849, respectively, which is included in other operating revenue in the Consolidated Statement of Operations and Changes in Net Assets. Management continues to monitor compliance with the terms and conditions of the Provider Relief Fund. If unable to attest to or comply with current or future terms and conditions, the System's ability to retain some or all of the distributions received may be impacted.

In April 2020, the System requested Medicare advanced payments under the Centers for Medicare and Medicaid Services' Accelerated and Advanced Payment Program (Program) designed to increase cash flow to Medicare providers and suppliers impacted by COVID-19. The Program allowed eligible health care facilities to request up to six months of advance Medicare

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

3. COVID-19 Pandemic and CARES Act Funding (continued)

payments for acute care hospitals or up to three months of advance Medicare payments for other health care providers. The System received approximately \$2,000,000 of advanced payments in April 2020. In accordance with the terms and conditions of the Medicare Advance Payment program, recoupments of approximately \$263 million occurred during the three months ended September 30, 2021 with a total of approximately \$462 million recouped to date.

4. Organizational Changes

Divestitures

During the three months ended September 30, 2021 and 2020, Ascension, including certain of its wholly owned subsidiaries, completed the sale of, or undertook actions to sell or transfer ownership of, certain assets and liabilities as follows.

Assets Held for Sale / Sold

Effective August 1, 2021, Ministry Health Care, Inc., a wholly owned subsidiary of Ascension, completed the transition of its sole membership interest in seven hospitals and related clinical and other business representing substantially all operations in the Northern and Central Wisconsin markets to Aspirus, Inc. Assets and liabilities held for sale at June 30, 2021 are \$355,312 and \$30,930, respectively, and are included in other current assets and other current liabilities in the Consolidated Balance Sheet at that date.

Effective August 1, 2020, Ascension St. Clare's Hospital, Inc., an Ascension Wisconsin subsidiary, completed the sale of certain of its assets and liabilities and substantially all related operations, as well as interests in two related joint ventures, to MCHS Hospitals, Inc., a subsidiary of Marshfield Clinic, Inc.

Membership Donation

Effective September 1, 2020, Ascension completed the separation of St. Mary's Healthcare, a wholly owned subsidiary of Ascension located in Amsterdam, New York. The separation was accounted for as a donation of unrestricted net assets of approximately \$135,000 included in other nonoperating gains (losses) and restricted net assets of approximately \$13,000 included in other net assets with donor restrictions in the Consolidated Statements of Operations and Changes in Net Assets.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

5. Pooled Investment Fund

At September 30, 2021 and June 30, 2021, respectively, a significant portion of long term investments consists of the Alpha Fund. The Alpha Fund, which is consolidated in the System's Consolidated Financial Statements, includes the investment interests of the System and other Alpha Fund members. Long term investments also include investments held by the Ministry Markets and their consolidated foundations, which are managed outside of the Alpha Fund.

AIM, a wholly owned subsidiary of the System, serves as the manager and primary investment advisor of the Alpha Fund, overseeing the investment strategies offered to the Alpha Fund's members. AIM provides expertise in the areas of asset allocation, selection and monitoring of outside investment managers, and risk management.

Ascension and the Alpha Fund invest in certain alternative investment funds which include contractual commitments to provide capital contributions during the investment period, which is typically five years and can extend to the end of the fund term. During these contractual periods, investment managers may require investment in accordance with the terms of the agreement.

Commitments not funded during the investment period will expire and remain unfunded. As of September 30, 2021, contractual agreements expire between November 2021 and May 2027.

The remaining unfunded capital commitments total approximately \$1,699,000 for 251 individual funds as of September 30, 2021. Due to the uncertainty surrounding whether the contractual commitments will require funding during the contractual period, future minimum payments to meet these commitments cannot be reasonably estimated. These committed amounts are expected to be primarily satisfied by the liquidation of existing investments in the Alpha Fund.

In the normal course of business, the Alpha Fund enters into derivative contracts (derivatives) for trading purposes following Alpha Fund guidelines. Advisers selected by AIM to manage the Alpha Fund's assets may actively trade futures contracts, options, swaps, forward settling mortgage-backed securities, index-based instruments, and foreign currency forward contracts. AIM may direct these advisers to execute derivative transactions. These transactions are used to hedge against changes in the interest rates, security prices, currency fluctuations, and other market developments to manage risk or for the purposes of earning additional income. Derivatives are either exchange-traded or over the counter contracts. Exchange-traded derivatives are standard contracts traded on a regulated exchange. Over the counter contracts are private contracts negotiated with counterparties.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

5. Pooled Investment Fund (continued)

See the Fair Value Measurements note for a discussion of how fair value for the Alpha Fund's derivatives is determined. At September 30, 2021 and June 30, 2021, the gross notional value of Alpha Fund derivatives outstanding was approximately \$13,561,000 and \$11,879,000, respectively.

The fair value of Alpha Fund derivatives in an asset position was \$115,723 and \$167,757 at September 30, 2021 and June 30, 2021, respectively, while the fair value of Alpha Fund derivatives in a liability position was \$38,545 and \$40,360 at September 30, 2021 and June 30, 2021, respectively. These derivatives are included in long-term investments in the Consolidated Balance Sheets.

Due from brokers and due to brokers on the Consolidated Balance Sheets represent the Alpha Fund's positions and amounts due from or to various brokers, primarily for security transactions not yet settled, and cash held by brokers for securities sold, not yet purchased.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

6. Cash and Investments

The System's cash and investments are reported in the Consolidated Balance Sheets as presented in the table that follows. Total cash and investments, net, includes both the System's membership interest in the Alpha Fund and the noncontrolling interests held by other Alpha Fund members. System unrestricted cash and investments, net, represent the System's cash and investments excluding the noncontrolling interests held by other Alpha Fund members and assets limited as to use.

	Sej	ptember 30, 2021	June 30, 2021
Cash and cash equivalents	\$	684,177	\$ 670,022
Short-term investments		96,464	97,222
Long-term investments		26,587,908	26,768,323
Subtotal		27,368,549	27,535,567
Other Alpha Fund assets and liabilities:			
In other current assets		32,005	32,969
In accounts payable and other accrued liabilities		(9,591)	(11,071)
In other noncurrent liabilities		(1,205)	(643)
Due (to) from brokers, net		(523,289)	(122,278)
Total cash and investments, net		26,866,469	27,434,544
Less noncontrolling interests of Alpha Fund		1,950,676	2,155,382
System cash and investments, including assets limited as to use		24,915,793	25,279,162
Less assets limited as to use:			
Under bond indenture agreement		1,208	1,177
Self-insurance trust funds		911,720	844,013
With donor restrictions		714,565	715,106
Total assets limited as to use		1,627,493	1,560,296
System unrestricted cash and investments, net	\$	23,288,300	\$ 23,718,866

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

6. Cash and Investments (continued)

The System's composition of cash and cash equivalents, short-term investments and long-term investments, which include certain assets limited as to use, is summarized as follows.

	Sej	ptember 30, 2021	June 30, 2021			
Cash and cash equivalents and short-term investments	s	836,033 \$	837,416			
Pooled short-term investment funds		1,701,480	1,502,891			
U.S. government, state, municipal and agency obligations		4,404,838	4,056,443			
Corporate and foreign fixed income securities		3,044,382	2,798,810			
Asset-backed securities		2,807,721	2,814,692			
Equity securities		7,670,213	8,507,145			
Alternative investments and other investments:						
Private equity and real estate funds		4,141,229	4,193,658			
Private credit and energy funds		1,470,464	1,450,386			
Hedge funds		959,318	989,114			
Other investments		332,871	385,012			
Total alternative investments and other investments		6,903,882	7,018,170			
Total cash and cash equivalents, short-term investments,						
and long-term investments	\$	27,368,549 \$	27,535,567			

Investment return recognized by the System for the three months ended September 30, 2021 and 2020, is summarized in the following table. Total investment return includes the System's return on certain investments held and managed outside the Alpha Fund and the investment return of the Alpha Fund. System investment return represents the System's total investment return, net of the investment return earned by the noncontrolling interests of other Alpha Fund members.

	The three months ended Septemb							
		2021	2020					
Interest and dividends	\$	61,476 \$	49,275					
Net gains (losses) on investments reported at fair value		(25,325)	1,298,159					
Restricted investment return and unrealized gains (losses), net		3,581	27,265					
Total investment return		39,732	1,374,699					
Less return earned by noncontrolling interests of Alpha Fund		7,438	75,455					
System investment return	\$	32,294 \$	1,299,244					

Total and system investment returns are net of external and direct internal investment expenses.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Financial Assets and Liquidity Resources

As of September 30, 2021 and June 30, 2021, respectively, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, principal payments on debt, and capital expenditures not financed with debt, are as follows:

Financial assets:	Se	ptember 30, 2021	June 30, 2021
Cash and cash equivalents	\$	684,177	\$ 670,022
Short-term investments		96,464	97,222
Accounts receivable		3,386,587	3,253,061
Due from brokers		117,059	97,225
Other current assets		858,867	1,120,666
Long-term investments		26,587,908	26,768,323
Total financial assets		31,731,062	32,006,519
Less:			
Assets limited as to use and other restricted funds		(1,693,951)	(1,653,166)
Noncontrolling interests of Alpha Fund		(1,950,676)	(2,155,382)
Investments with liquidity more than one year		(5,062,253)	(4,897,829)
Total financial assets available within one year		23,024,182	23,300,142
Liquidity resources:			
Unused lines of credit		600,000	600,000
Total financial assets and liquidity resources available			
within one year	\$	23,624,182	\$ 23,900,142

As part of the System's investment policy, highly liquid investments are held to enhance the System's ability to satisfy liquidity requirements. The System also maintains lines of credit.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements

The System measures the fair value of assets and liabilities in accordance with FASB ASC 820, Fair Value Measurement. Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability at the measurement date. Assets and liabilities reported at fair value are classified and disclosed in one of the following four categories:

Level 1 – Quoted prices (unadjusted) that are readily available in active markets/exchanges for identical assets or liabilities.

Level 2 – Pricing inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 pricing inputs include prices quoted for similar assets and liabilities in active markets/exchanges or prices quoted for identical or similar assets and liabilities in markets that are not active. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Significant pricing inputs that are unobservable for the asset or liability, including assets or liabilities for which there is little, if any, market activity for such asset or liability. Inputs to determine the fair value of Level 3 assets and liabilities require management judgment and estimation.

Net Asset Value – Values are based on the calculated net asset value. The calculated net asset values for underlying investments are fair value estimates determined by an external fund manager and other sources based on quoted market prices, operating results, balance sheet stability, growth, and other business and market sector factors.

The System categorizes, for disclosure purposes, assets and liabilities measured at fair value in the Consolidated Financial Statements based upon whether the inputs used to determine their fair values are observable or unobservable. Observable inputs are inputs that are based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about pricing the asset or liability based on the best information available in the circumstances.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an asset's or liability's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement of the asset or liability. The System's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

As of September 30, 2021, and June 30, 2021, the assets and liabilities listed in the fair value hierarchy tables below use the following valuation techniques and inputs:

Cash and Cash Equivalents and Short-Term Investments

Cash and cash equivalents and certain short-term investments include certificates of deposit, whose fair value is based on cost plus accrued interest. Significant observable inputs include security cost, maturity, and relevant short-term interest rates.

Other short-term investments designated as Level 2 investments primarily consist of commercial paper, whose fair value is based on the income approach. Significant observable inputs include security cost, maturity, credit rating, interest rate, and par value.

Pooled Short-Term Investment Fund

The pooled short-term investment fund is a short-term exchange traded money market fund primarily invested in treasury securities.

U. S. Government, State, Municipal, and Agency Obligations

The fair value of investments in U.S. government, state, municipal, and agency obligations is primarily determined using techniques consistent with the income approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, and issuer spreads.

Corporate and Foreign Fixed Income Securities

The fair value of investments in U.S. and international corporate bonds and foreign government bonds is primarily determined using techniques that are consistent with the market approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, issuer spreads, and security-specific characteristics (e.g., such as early redemption options).

Asset-backed Securities

The fair value of U.S. agency, mortgage, and other asset-backed securities is primarily determined using techniques that are consistent with the income approach. Significant observable inputs include prepayment speeds and spreads, benchmark yield curves, volatility measures, and observable broker/dealer quotes.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

Equity Securities

The fair value of investments in U.S. and international equity securities is primarily determined using techniques that are consistent with the market and income approaches. The values for underlying investments are based on readily available quoted market prices or represent fair value estimates determined by an external fund manager based on market prices, operating results, balance sheet stability, growth, dividend, dividend yield, and other business and market sector fundamentals.

Alternative Investments and Other Investments

Alternative investments consist of private equity, hedge funds, private equity funds, private credit and energy funds, and real estate partnerships. The fair value of private equity is primarily determined using techniques consistent with both the market and income approaches, based on the System's estimates and assumptions in the absence of observable market data. The market approach considers comparable company, comparable transaction, and company-specific information, including but not limited to restrictions on disposition, subsequent purchases of the same or similar securities by other investors, pending mergers or acquisitions, and current financial position and operating results. The income approach considers the projected operating performance of the portfolio company.

The fair value of hedge funds, private equity funds, private credit and energy funds, and real estate partnerships is primarily determined using net asset values, which approximate fair value, as determined by an external fund manager based on quoted market prices, operating results, balance sheet stability, growth, and other business and market sector fundamentals.

Other investments include derivative assets and derivative liabilities of the Alpha Fund, whose fair value is primarily determined using techniques consistent with the market approach. Significant observable inputs to valuation models include the time value of money, counterparty credit risk, interest rates, Treasury yields, volatilities, credit spreads, maturity date, recovery rates, and the current market and contractual prices of the underlying financial instruments.

Benefit Plan Assets

The fair value of benefit plan assets is based on original investment into a guaranteed fund, plus guaranteed, annuity contract-based interest rates. Significant unobservable inputs to the guaranteed rate include the fair value and average duration of the portfolio of investments underlying annuity contract, the contract value, and the annualized weighted-average yield to maturity of the underlying investment portfolio.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

Interest Rate Swap Assets and Liabilities

The fair value of interest rate swaps is primarily determined using techniques consistent with the income method. Under the income method, fair values are calculated based on present value of expected future cash flows using discount rates appropriate with risks involved.

Significant observable inputs to valuation models include interest rates, Treasury yields, volatilities, credit spreads, maturity, and recovery rates.

Investments Sold, Not Yet Purchased

The fair value of investments sold, not yet purchased is primarily determined using techniques consistent with the income approach. Significant observable inputs to the income approach include data points for benchmark, constant maturity curves, and spreads.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

The following table summarizes fair value measurements, by level, at September 30, 2021, for all financial assets and liabilities measured at fair value on a recurring basis in the System's Consolidated Financial Statements:

		Level 1	Level 2	Level 3	Total		
September 30, 2021							
Cash equivalents	\$	19,343	\$	2,375	\$ -	\$	21,718
Short-term investments		64,115		10,087	-		74,202
Pooled short-term investment funds]	1,701,480		-	-		1,701,480
U.S. government, state, municipal							
and agency obligations		_		4,404,838	-		4,404,838
Corporate and foreign fixed income securities		_		3,029,009	15,373		3,044,382
Asset-backed securities		_		2,364,256	443,465		2,807,721
Equity securities	5	5,765,652		17,083	34,879		5,817,614
Alternative investments and other investments:							
Private equity and real estate funds		_		-	663,249		663,249
Other investments		45,321		209,051	3,486		257,858
Assets at net asset value:							
Equity securities							1,852,599
Private equity and real estate funds							3,477,482
Private credit and energy funds							1,470,464
Hedge funds							959,318
Other investments							5,683
Cash and other investments not at fair value							809,941
Cash and investments						\$	27,368,549
Benefit plan assets, in other noncurrent assets	\$	679,247	\$	17,776	\$ 58,946	\$	755,969
Interest rate swaps, in other noncurrent assets		-		2,210	-		2,210
Investments sold, not yet purchased, in other noncurrent liabilities		740		465	-		1,205
Interest rate swaps, included in other noncurrent liabilities		-		118,057	-		118,057

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

For the three months ended September 30, 2021, the changes in the fair value of the assets and liabilities measured using significant unobservable inputs (Level 3) consisted of the following:

								Private				
	Corp	orate and		Asset-			E	quity and				
	Foreign Fixed		Backed		Equity		Re	eal Estate		Other	Bei	ıefit Plan
	Income	e Securities	S	ecurities	Se	ecurities		Funds	In	vestments	1	Assets
The three months ended												
September 30, 2021												
Beginning balance	\$	8,009	\$	479,273	\$	33,151	\$	733,753	\$	3,711	\$	58,504
Realized and unrealized gains (losses):												
Included in nonoperating gains (losses)		1,103		168		1,846		8,602		(223)		_
Included in changes in net assets		-		-		-		-		7		-
Purchases		11,413		42,512		20		8,607		54		1,265
Issuances		-		-		-		2,337		-		-
Sales		(3,722)		(70,099)		(138)		(90,050)		(63)		(1,897)
Transfers into Level 3		-		7,151		-		-		-		1,730
Transfers out of Level 3		(1,430)		(15,540)		-		-		-		(656)
Ending balance	\$	15,373	\$	443,465	\$	34,879	\$	663,249	\$	3,486	\$	58,946
The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in												
unrealized gains or losses relating to assets												
still held at June 30, 2021	\$	920	\$	148	\$	1,759	\$	-	\$	(276)	\$	

The basis for recognizing and valuing transfers into or out of Level 3, in the Level 3 rollforward, is as of the beginning of the period in which the transfers occur.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

The following table summarizes fair value measurements, by level, at June 30, 2021, for all financial assets and liabilities measured at fair value on a recurring basis in the System's Consolidated Financial Statements:

•	Level 1	Level 2	Level 3	Total		
June 30, 2021						
Cash equivalents	\$ 19,508	\$	3,826	\$ -	\$	23,334
Short-term investments	78,134		9,962	-		88,096
Pooled short-term investment funds	1,502,891		-	-		1,502,891
U.S. government, state, municipal						
and agency obligations	-		4,056,443	-		4,056,443
Corporate and foreign fixed income securities	-		2,790,801	8,009		2,798,810
Asset-backed securities	-		2,335,419	479,273		2,814,692
Equity securities	6,570,042		13,912	33,151		6,617,105
Alternative investments and other investments:						
Private equity and real estate funds	-		2,500	733,753		736,253
Other investments	215,024		96,079	3,711		314,814
Assets at net asset value:						
Equity securities						1,890,040
Private equity and real estate funds						3,456,906
Private credit and energy funds						1,450,386
Hedge funds						989,114
Other investments						5,343
Cash and other investments not at fair value						791,340
Cash and investments					\$	27,535,567
Benefit plan assets, in other noncurrent assets	\$ 657,870	\$	17,381	\$ 58,504	\$	733,755
Interest rate swaps, in other noncurrent assets	-		2,497	-		2,497
Investments sold, not yet purchased, in other noncurrent liabilities	175		469	-		644
Interest rate swaps, included in other noncurrent liabilities	-		126,554	-		126,554

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Fair Value Measurements (continued)

For the three months ended September 30, 2020, the changes in the fair value of the assets and liabilities measured using significant unobservable inputs (Level 3) consisted of the following:

	orporate and oreign Fixed		Asset-				Private quity and				
	Income Backed		Equity Real Estate				Other	Benefit Plan			
	Securities	S	ecurities	Se	curities		Funds	In	vestments		Assets
The three months ended											
September 30, 2020											
Beginning balance	\$ 7,489	\$	734,511	\$	20,921	\$	351,731	\$	3,817	\$	59,435
Realized and unrealized gains (losses):											
Included in nonoperating gains (losses)	(119)		27,295		(373)		86,424		(117)		-
Included in changes in net assets	-		-		-		(25)		7		-
Purchases	-		14,128		1,551		15,000		1		1,532
Sales	(1,828)		(47,911)		(571)		(2,673)		-		(3,359)
Transfers into Level 3	4,551		3,720		1,399		-		-		9,862
Transfers out of Level 3	-		(105,672)		-		-		(1,310)		(184)
Ending balance	\$ 10,093	\$	626,071	\$	22,927	\$	450,457	\$	2,398	\$	67,286
The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in unrealized gains or losses relating to assets still held at June 30, 2020	\$ (132)	\$	26,854	\$	(177)	•		\$	84	\$	

The basis for recognizing and valuing transfers into or out of Level 3, in the Level 3 rollforward, is as of the beginning of the period in which the transfers occur.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

9. Derivative Instruments

As provided for in the System's Master Trust Indenture, the System uses interest rate swap agreements to manage interest rate risk associated with its outstanding debt. These swaps have historically been used to effectively convert interest rates on variable rate bonds to fixed rates and rates on fixed rate bonds to variable rates. At September 30, 2021 and June 30, 2021, the notional values of outstanding interest rate swaps were \$892,920 and \$894,445, respectively.

The System recognizes the fair value of its interest rate swaps in the Consolidated Balance Sheets as assets, recorded in other noncurrent assets, or liabilities, recorded in other noncurrent liabilities, as appropriate. The System does not offset fair value amounts recognized for derivative instruments. The fair value of interest rate swaps in an asset position was \$2,210 and \$2,497 at September 30, 2021 and June 30, 2021, respectively. The fair value of interest rate swaps in a liability position was \$118,057 and \$126,554 at September 30, 2021 and June 30, 2021, respectively.

The System's interest rate swap agreements include collateral requirements for each counterparty under such agreements, based upon specific contractual criteria, subject to master netting arrangements. Collateral requirements are calculated based on the System's credit ratings. The applicable credit rating is the Senior Credit Group long-term debt credit ratings (Senior Debt Credit Ratings), as obtained from each of two major credit rating agencies. Credit rating and the net liability position of total interest rate swap agreements outstanding with each counterparty determine the amount of collateral to be posted. No collateral was posted as of September 30, 2021 and June 30, 2021.

The System does not designate its interest rate swaps as hedges, and accordingly, all changes in the fair value of interest rate swaps are recognized in nonoperating gains (losses) in the Consolidated Statements of Operations and Changes in Net Assets.

10. Leases

The System is a party to primarily real estate and medical and information technology equipment leases as a lessee and real estate leases as a lessor. Many leases include rental escalation clauses or renewal options which are factored into the determination of lease payments when appropriate. As most of the System's operating leases do not provide an implicit rate, the System uses its incremental borrowing rate based upon information available at the lease commencement date in determining the present value of lease payments. In addition, the System does not separate lease and non-lease components.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

10. Leases (continued)

All components of total lease cost are recognized in other operating expenses, excluding interest on finance lease liabilities, which is recognized in interest. The following table provides the total lease cost included in the Consolidated Statement of Operations and Changes in Net Assets:

	The three months ended September 3					
		2021		2020		
Operating lease cost	\$ 90,884		\$	81,944		
Finance lease cost:						
Interest on lease liabilities		726		769		
Amortization of right-of-use-asset		710		943		
Variable lease cost		15,788		18,011		
Total lease cost	\$	108,108	\$	101,667		

The weighted average remaining lease terms and the weighted average discount rates at September 30, 2021 and September 30, 2020 were as follows:

	Septembe	September 30, 2021 September 30, 20		r 30, 2020
	Operating	Finance	Operating	Finance
	Leases	Leases	Leases	Leases
Weighted-average remaining lease term	8.4 years	28.3 years	8.6 years	29.3 years
Weighted-average discount rate	2.5%	3.3%	2.8%	3.3%

The following table provides the cash paid for amounts included in the measurement of lease obligations:

	The three months ended September 30,				
		2021		2020	
Operating leases	\$	88,158	\$	85,383	
Finance leases		1,003		1,468	
Total cash paid	\$	89,161	\$	86,851	

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

10. Leases (continued)

The following table reconciles undiscounted future operating and finance lease obligations for each of the next five years and thereafter, as of September 30, 2021, to lease obligations recorded on the Consolidated Balance Sheets at September 30, 2021.

	O	perating	F	inance				
Three months ended September 30:		Leases		Leases		Leases	Total	
2022	\$	274,100	\$	3,863	\$	277,963		
2023		236,609		3,930		240,539		
2024		191,648		3,999		195,647		
2025		145,844		4,069		149,913		
2026		117,637		4,141		121,778		
Thereafter		443,174	1	14,302		557,476		
Total future undiscounted lease obligations	1	,409,012	1	34,304	1	1,543,316		
Less: amount of lease payments representing interest		(151,960)	(51,110)		(203,070)		
Present value of future lease obligations	1	,257,052		83,194	1	1,340,246		
Less: current portion of lease obligations		(247,481)		(909)		(248,390)		
Long-term lease obligations	\$1	,009,571	\$	82,285	\$ 1	1,091,856		

For leases where the System is a lessor, future minimum noncancelable receipts on operating leases for each of the next five years and thereafter, as of September 30, 2021, are as follows:

	Oı	perating	
Three months ended September 30:	Leases		
2022	\$	64,623	
2023		50,242	
2024		39,271	
2025		29,933	
2026		21,973	
Thereafter		330,319	
Total	\$	536,361	

For both three month periods ended September 30, 2021 and 2020, lease income was approximately \$19,000.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

11. Retirement Plans

Certain System entities participate in defined-benefit pension plans (the System Plans), which are noncontributory, defined-benefit pension plans. Benefits are based on each participant's years of service and compensation. Primarily all of the System Plans' assets are invested in the Master Pension Trust (the Trust).

The System Plans' assets primarily consist of equity securities, U.S. government, state, municipal and agency obligations, asset-backed securities, and alternative investments including primarily private equity and real estate funds.

Contributions to the System Plans are based on actuarially determined amounts sufficient to meet the benefits to be paid to participants. As of December 31, 2019, all System Plans were frozen.

The assets of the System Plans are available to pay the benefits of eligible employees and retirees of all participating entities. In the event entities participating in the System Plans are unable to fulfill their financial obligations under the System Plans, the other participating entities are obligated to do so.

The following table provides the components of net periodic benefit costs for the System included in Other non-operating gains (losses) in the Consolidated Statements of Operations and Changes in Net Assets.

	Three months ended September 30,				
	2021	2020			
Components of net periodic benefit gain					
Interest cost	(73,874)	(75,476)			
Expected return on plan assets	171,431	165,117			
Amortization of prior service credit	(73)	(64)			
Amortization of actuarial loss	(37,834)	(40,727)			
Net periodic benefit gain	\$ 59,650 \$	48,850			

12. Contingencies and Commitments

The System is involved in litigation and regulatory investigations arising in the ordinary course of business. In the opinion of management, after consultation with legal counsel, these matters are expected to be resolved without material adverse effect on the System's Consolidated Balance Sheets.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

12. Contingencies and Commitments (continued)

The System enters into agreements with non-employed physicians that include minimum revenue guarantees. The terms of the guarantees vary. The maximum amount of future payments that the System could be required to make under these guarantees is approximately \$6,300.

The System has entered into Master Service Agreements for information technology services provided by third parties, under which future committed payments of approximately \$764,000 will be made over the upcoming 3 to 5 years.

Guarantees and other commitments represent contingent commitments issued by Ascension Health Alliance Senior and Subordinate Credit Groups, generally to guarantee the performance of an affiliate to a third party in borrowing arrangements such as commercial paper issuances, bond financing, and other transactions. The terms of guarantees are equal to the terms of the related debt, which can be as long as 18 years.

The following represents the remaining guarantees and other commitments of the Senior and Subordinate Credit Groups at September 30, 2021:

Hospital de la Concepción 2017 Series A debt guarantee	\$ 20,085
St. Vincent de Paul Series 2000 A debt guarantee	28,300
Other guarantees and commitments	53,087

13. Functional Expenses

Ascension provides healthcare services, including inpatient, outpatient, ambulatory, long-term care and community-based services. Management support services include administration, finance and accounting, revenue cycle, information technology, public relations, human resources, legal, supply chain, risk management, compliance and other functions. Expenses are allocated to healthcare services and management support services based on the functional department for which they are incurred. Departmental expenses may include various allocations of costs based on direct assignment, expenses or other methods.

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

13. Functional Expenses (continued)

Expenses by functional classification for the three months ended September 30, 2021 consist of the following:


Three months ended September 30, 2021

	Health care services	Managemen support services	t Total
Salaries, wages, and employee benefits	\$ 3,141,885	\$ 275,966	\$ 3,417,851
Purchased services and professional fees	816,105	315,934	1,132,039
Supplies	1,053,583	446	1,054,029
Other	1,206,685	113,365	1,320,050
Total operating expenses	\$ 6,218,258	\$ 705,711	\$ 6,923,969

Expenses by functional classification for the three months ended September 30, 2020 consist of the following:

Three months ended September 30, 2020

Management				
Health care services				Total
\$2,987,886	\$	239,683	\$	3,227,569
768,640		258,077		1,026,717
975,126		9,070		984,196
1,157,204		109,155		1,266,359
\$5,888,856	\$	615,985	\$	6,504,841
	\$2,987,886 768,640 975,126 1,157,204	Health care services : \$2,987,886 \$ 768,640 975,126 1,157,204	Health care services support services \$2,987,886 \$ 239,683 768,640 258,077 975,126 9,070 1,157,204 109,155	Health care services support services \$2,987,886 \$ 239,683 \$ 768,640 \$ 258,077 975,126 9,070 \$ 1,157,204 \$ 109,155



Schedule of Net Cost of Providing Care of Persons Living in Poverty and Other Community Benefit Programs (Dollars in Thousands)


Three Months Ended September 30, 2021 and 2020

The net cost of providing care to persons living in poverty and other community benefit programs is as follows:

	The three months ended			
		Septen	ıber	30,
		2021		2020
Traditional charity care provided	\$	106,136	\$	137,878
Unpaid cost of public programs for persons				
living in poverty		350,516		292,648
Other programs for persons living in poverty				
and other persons who are vulnerable		19,284		19,009
Community benefit programs		86,230		91,371
Care of persons living in poverty and other community				
benefit programs	\$	562,166	\$	540,906

Management's Discussion and Analysis of Financial Condition and Results of Operations for Ascension

As of and for the three months ended September 30, 2021 and 2020



The following information should be read in conjunction with Ascension's consolidated financial statements and related notes to the consolidated financial statements.

Introduction to Management's Discussion and Analysis


The purpose of Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is to provide a narrative explanation of the financial position and operations of Ascension (the System).

The MD&A includes the following sections:

- Organization and Mission
- Executive Overview
- Organizational Changes
- Novel Coronavirus (COVID-19)
- Select Financial Information

Organization and Mission

Ascension is a faith-based healthcare organization dedicated to transformation through innovation across the continuum of care. As one of the largest non-profit and Catholic health systems in the U.S., Ascension is committed to its Mission, Vision, and Values by delivering compassionate, personalized care to all, with special attention to persons living in poverty and those most vulnerable. At September 30, 2021, the System included approximately 145,000 associates and 40,000 aligned providers, operating more than 2,600 sites of care including 141 hospitals and approximately 40 senior living facilities - in 19 states and the District of Columbia, while providing a variety of healthcare-related services including clinical and managed care services. investment management (including venture capital and direct strategic investing), facilities management, management, and contracting through Ascension's own group purchasing organization.



Executive Overview

For the three months ended September 30, 2021 (Q1 FY22), Ascension's operations and volumes continued to experience volatility as a result of recurrent surges of the COVID-19 pandemic, most notably in our southern markets. During Q1 FY22, our System experienced the second highest inpatient census for COVID patients since the onset of the pandemic. Localized intermittent COVID-related restrictions also resulted in the cancellation or deferral of elective procedures at certain times in select markets throughout the quarter. Ascension remains committed to managing operations to focus on our top priorities of caring for our patients and caregivers.

Organizational Changes

Ascension continues to make strategic and purposeful decisions to improve the health of individuals and communities served, engage with consumers in new ways, and support the shift to expanded ambulatory and telehealth presence. To strengthen hospital operations and gain capabilities for the future, the organization's changes to its portfolio are as follows.

Effective August 1, 2020, Ascension divested certain assets and liabilities and substantially all related operations of Ascension St. Clare's Hospital in Weston, Wisconsin, to Marshfield Clinic Health System.

Effective September 1, 2020, St. Mary's Healthcare in Amsterdam, New York, separated from the Ascension System and began to operate as an independent, Catholic healthcare organization under the governance of a local Board.

Effective August 1, 2021, Ministry Health Care, Inc., a wholly owned subsidiary of Ascension, transitioned its sole membership interest in seven hospitals and related clinical and other business, representing substantially all operations in the Northern and Central Wisconsin markets, to Aspirus, Inc.

Subsequent to September 30, 2021 in October 2021, Ascension and AdventHealth announced the intention to unwind the AMITA Health joint operating company partnership. Both organizations are united in their commitment to continue to serve healthcare needs in the greater Chicago area.

Novel Coronavirus (COVID-19)

The global novel coronavirus (COVID-19) pandemic has had significant economic and operational impact on the U.S. healthcare industry. Ascension's patients, employees, business operations and communities served by the System continue to be impacted by the uncertainty of the pandemic.

Recurrent surges of COVID-19 cases across the nation during the three months ended September 30, 2021 continued to have an impact on Ascension's volumes and created unprecedented operational and financial challenges as further discussed below. Healthcare utilization hesitation, along with vaccination hesitation continues to impact Ascension's markets to varying degrees, as the System's volumes remain below pre-pandemic levels for the comparable quarter in all categories except physician office and clinic visits. During Q1 FY22, governmental relief funds and programs helped to offset the adverse financial impacts of the pandemic although to a much lesser extent than the comparable quarter of the prior year. The System was able to absorb the additional operating expense impacts through expansion and growth in certain other operations and strong stewardship consistent with our Mission to serve our patients, with special attention to persons living in poverty and those most vulnerable, along with our caregivers.

The System recognized revenue associated with distributions from the CARES Act during 01 of FY22 and FY21. The CARES Act increased funding for the Public Health and Social Services Emergency Fund (Provider Relief Fund) to reimburse eligible healthcare providers for lost revenues or healthcare-related expenses attributable COVID-19, as well as increased Medicare reimbursement rates for inpatients diagnosed with COVID-19. For Q1 FY22, the System recognized revenue associated with Provider Relief Fund payments of approximately \$4 million, representing a significant decrease from the \$185 million of Provider Relief Fund payments recognized during the respective quarter of the prior fiscal year. The recognition of the Provider Relief Fund payments is included within Other operating revenue in the Consolidated Statement of Operations and Changes in Net Assets.

Select Financial Information (dollars in millions)

Consolidated Operations

The following table reflects selected financial information on a consolidated basis for the three months ended September 30, 2021 and 2020.

Three months ended September 30,

	2021	2020
Net Patient Service Revenue	\$ 6,384	\$ 5,977
Other Operating Revenue	553	650
Operating Expenses	6,924	6,505
Income (loss) from Operations	25	143
Operating Margin	0.4%	2.2%
Operating EBIDA Margin	5.9%	8.0%
Cost of Providing Care of Persons Living in Poverty and Other Community Benefit Programs	562	541

On a consolidated basis, operating margin was 0.4% for the three months ended September 30, 2021, as compared to 2.2% for the same quarter in the prior year. Operating EBIDA margin was 5.9% for the three months ended September 30, 2021, as compared to 8.0% in the same quarter of the prior year. Decreases in margins are impacted by the aforementioned decrease in government funding intended to offset losses incurred during the pandemic.

Volume Trends

The following table reflects certain patient volume information, on a consolidated basis, for the three months ended September 30, 2021 and 2020.

Three months ended September 30,

Volume Trends
Equivalent Discharges
Total Admissions
Case Mix Index
Surgery Visits (IP & OP)
Emergency Room Visits
Urgent Care Visits
Physician Office and Clinic Visits
Virtual Provider Office (VPO) Visits

2021	2020	
399,315	391,997	
191,115	186,759	
1.83	1.82	
145,774	151,478	
790,686	669,155	
147,586	111,616	
4,068,251	3,840,640	
272,994	386,995	

During the three months ended September 30, 2021, the System experienced increased volumes representing the impact of caring for patients through the most recent and significant COVID surge while also continuing the recovery of pandemic-impacted volumes in certain categories. Equivalent discharges, admissions, emergency room visits, urgent care visits and physician office and clinic visits for Q1 FY22 were greater than the same quarter in the prior year by 1.9%, 2.3%, 18.2%, 32.2% and 5.9%, respectively. However, total surgery visits were less than the same quarter in the prior year by 3.8% largely driven by lower inpatient surgeries.

On a same facility basis, volume comparisons to the same quarter in the prior year were even more favorable. Equivalent discharges, admissions, emergency room visits, urgent care visits and physician office and clinic visits increased by 3.8%, 3.6%, 20.5%, 41.7% and 7.8%, respectively. Total same facility surgery visits for the three months ended September 30, 2021 were 1.8% less than the same quarter in the prior year; however, same facility outpatient surgeries increased 2.2% for the same comparison.

For the three months ended September 30, 2021, VPO visits decreased 29.5% from the same quarter in the prior year, at which time VPO visits were exceptionally high at $\sim 10\%$ of total physician visits as a greater proportion of the visits were still virtual after the onset of the pandemic. Overall, outpatient visits have been increasing with Q1 FY22 volumes improving 1.4% or 5.4% on a same facility basis over Q1 FY21.

Total Operating Revenue



- Provider Relief Fulldling and Other Fandeniic Grants
- Other Operating Revenue (excl. PRF)
- Net Patient Service Revenue

Total operating revenue increased by \$310 million or 4.7% during the three months ended September 30, 2021, as compared to the same quarter in the prior year.

Net patient service revenue (NPSR) remains impacted by the pandemic including the recent surge as the System experienced an increase over prior year in NPSR of \$0.4 billion or 6.8% for the three months ended September 30, 2021. The System's same facility operations have shown growth in NPSR of 8.9% for the three months ended September 30, 2021, as compared to the same period in the prior year. NPSR also exceeded pre-pandemic levels by 5.4%.

For the three months ended September 30, 2021, NPSR per equivalent discharge increased 4.8%, or 5% on a same facility basis compared to the prior year. Aside from the previously mentioned volume increases, NPSR growth was impacted by improved rate and yield due to moderate inflationary increases in payor payments and a slight increase in the System's case mix index (which has been at historically high levels over the past year) due to higher-acuity patients, including COVID-positive patients, seeking care during the recent surge of the pandemic.

Total other operating revenue decreased by \$97 million or 14.9% during the three months ended September 30, 2021, as compared to the same quarter in the prior year. The


decrease in other operating revenue is primarily due to the previously mentioned decrease in CARES Act Provider Relief Funding recognized as compared to the prior period. Gains on sales, growth in pharmacy service lines and joint venture performance helped offset the decrease in Provider Relief Funds during Q1 FY22.

One-time gains on sale of assets of \$78 million were recorded in other operating revenue during the three months ended September 30, 2021, representing an increase of \$41 million over the prior year.

Pharmacy service revenue of \$138 million increased 18.6% for the three months ended September 30, 2021, as compared to the same period in the prior year. Increased volume of retail operations, in-house processing of specialty pharmacy needs, and increased 340b volumes contributed to this increase in other operating revenue.

Unconsolidated joint venture performance of \$70 million also improved 21.4% over the same quarter in the prior year.

Total Operating Expenses



Total operating expenses increased \$419 million or 6.4% during the three months ended September 30, 2021, as compared to the same quarter in the prior year. Incremental pandemic-related salaries, wages, employee benefits, purchased services, and supply expenses contributed to the System's overall expense increase, along with other expected increases from normal operations as further discussed below. The System's

focused efforts to manage non-patient-facing expenses such as travel and other variable expenses, while supporting the workforce to care for patients, continues to be a top priority.

The System experienced a 4.5% increase in cost per equivalent discharge during the three months ended September 30, 2021, primarily due to the increases in direct costs from the pandemic as previously discussed. The treatment of COVID positive patients through the recent surge has led to an increase in the average length of stay, along with increased caregiver compensation and supply costs.

Total salaries, wages and benefits increased \$190 million, or 5.9%, for the three months ended September 30, 2021, compared to the same quarter in the prior year. The increase is primarily due to staffing challenges including increased utilization of contract and premium labor and market wage adjustments as a result of the additional COVID surges for the pandemic along with onboarding additional physicians.

Purchased services increased \$89 million, or 12.6%, for the three months ended September 30, 2021, as compared to the same quarter in the prior year as increased volumes and NPSR resulted in higher outsourced revenue cycle fees and purchased medical services.

Supply expenses increased \$70 million, or 7.1%, during the three months ended September 30, 2021, as compared to the same period in the prior year. Increased inpatient COVID census seen during the pandemic surges resulted in the use of more costly pharmaceuticals, COVID-related lab and testing supplies, as well as increased use of personal protective equipment, contributing to a ~70% increase in COVID-related supplies over the same quarter in the prior year. Other increases in supplies were driven by volume increases.

Other operating expenses (includes professional fees, insurance, provider tax, income tax and other operating expenses) increased \$70 million, or 4.4%, for the three months ended September 30, 2021, as compared to the same quarter in the prior year due to an increase in cost of goods sold associated with the increased pharmacy revenue discussed above, increased physician fees and insurance expenses.

Non-Operating Income - Investment Return

Substantially all the System's cash and investments are invested in a broadly diversified portfolio that is managed by Ascension Investment Management (AIM), a wholly owned subsidiary of Ascension. Total net investments under management by AIM, including non-Ascension investors, were \$50.1 billion at September 30, 2021.

Ascension's long-term investment pools, excluding noncontrolling interests and long-term investments held by self-insurance programs, experienced volatility and moderation with a return of 1.5% during the three months ended September 30, 2021. While the net return for the three months ended September 30, 2021 was \$33 million, investment income in the same quarter of the prior fiscal year was \$1.3 billion.

Financial Position

Ascension's balance sheet and liquidity levels remain strong with more than sufficient liquidity to continue to provide care for patients, despite the economic challenges resulting from the pandemic. The following table reflects selected financial information on a consolidated basis.

	9/30/2021	6/30/2021	
Current Assets	\$ 5,951	\$ 5,981	
Long-Term Investments	26,588	26,768	
Property and Equipment	11,017	11,067	
Other Assets	4,563	4,583	
Total Assets	\$ 48,119	\$ 48,399	

	9/30/2021	6/30/2021
Current Liabilities	\$ 7,495	\$ 7,244
Long-Term Liabilities	11,537	11,879
Total Liabilities	19,032	19,123
Net Assets	29,087	29,276
Total Liabilities and Net Assets	\$ 48,119	\$ 48,399

Financial Assets and Liquidity Resources

The System's cash and investment position remains strong and includes highly liquid investments. Net unrestricted cash and investments were \$23.3 billion at September 30, 2021, which is approximately 48% of the System's total assets. The System's days cash on hand was 325 days as of September 30, 2021, as further discussed below.

Additionally, Ascension maintains two lines of credit, totalling \$600 million. As of September 30, 2021, there were no outstanding borrowings under either line of credit. Both lines of credit are committed through December 1, 2021. The System also has access to a \$1.0 billion taxable commercial paper program.

During fiscal year 2020, Ascension applied for and received approximately \$2.0 billion of Medicare Advance Payments. The advanced payments are recorded within long-term investments and current and long-term liabilities on the System's Consolidated Balance Sheets. Medicare Advance Payments represent approximately 21 and 26 days cash as of September 30, 2021, and June 30, 2021, respectively. In addition, Ascension has deferred employer payroll tax payments pursuant to the Paycheck Protection Program and Health Care Enhancement Act that represent approximately 5 days cash in both periods.

In accordance with the terms and conditions of the Medicare Advance Payment program, recoupments of approximately \$263 million occurred during the three months ended September 30, 2021 with a total of \$462 million recouped to date.

Balance Sheet Ratios

Days Cash on Hand

Net Days in Accounts
Receivable

Cash-to-Debt

Total Debt to
Capitalization

Debt Service
Coverage

9/30/2021	6/30/2021
325	341
48.7	47.3
310.1%	315.2%
22.5%	22.6%
12.11	11.04

The System's Master Trust Indenture requires Ascension to maintain an annual debt service coverage ratio of 1.10 and Ascension was well above this covenant at September 30, 2021.

Net days in accounts receivable increased slightly from 47.3 days at June 30, 2021, to 48.7 days at September 30, 2021.

Care of Persons Living in Poverty and Community Benefit

Ascension provided \$0.6 billion in Care of Persons Living in Poverty and Other Community Benefit Programs for the three months ended September 30, 2021. Through programs, donations, health education, trauma programs, free care and more, the organization's uncompensated care and other community benefits fulfill unmet needs in the communities we serve.

Care of Persons Living in Poverty and Other Vulnerable Persons (dollars in millions)



- Other Programs for the General Community (IV)
- Other Programs for Persons Living in Poverty (III)
- Unpaid Cost of Public Programs (II)
- Traditional Charity Care (I)
- Categories I IV as a % of Total Operating Expense

The total cost of providing care to persons living in poverty and other community benefit programs increased as compared to the same period in the prior year, primarily

due to an increase in patient volumes, particularly for patients insured through public programs. As discussed above, the System experienced an increase in emergency room volumes driven by the additional pandemic surges and continued recovery of other volumes from the pandemic period during Q1 FY22. The emergency room has historically served as the primary entry point to health care for uninsured populations, patients qualifying for charity care and patients insured through public programs.

The System experienced an increase in Medicaid gross charges and equivalent discharges throughout the three months ended September 30, 2021 compared to the same quarter in the prior year. Such increases further contributed to a decrease in the System's traditional charity care provided during the three months ended September 30, 2021, as compared to the same period in the prior year as more patients were eligible and shifted to public programs (i.e., Medicaid) in select markets.

The System continues to deliver compassionate, personalized care to all, with special attention to persons living in poverty and those most vulnerable, despite the continued pandemic-related challenges experienced during the three months ended September 30, 2021.

Consolidated Statistical Information For the Three Months Ended

	September 30,	
	2021	2020
<u>Discharges by Service Type</u>		
Acute Care	174,334	170,029
Psychiatric Care	10,998	11,478
Rehabilitation Care	2,859	2,833
Skilled Nursing Facility Care and Residential Living	251	296
Long Term Acute Care	334	367
Other L.T. Sub-Acute Care	2,339	1,756
Total Discharges by Service	191,115	186,759
Patient Days by Service Type		
Acute Care	900,538	801,593
Psychiatric Care	80,997	79,301
Rehabilitation Care	33,845	34,850
Skilled Nursing Facility Care	225,788	302,189
Assisted Living	50,572	59,394
Residential Living	2,827	4,434
Long Term Acute Care	11,059	11,724
Other L.T. Sub-Acute Care	139,336	152,341
Total Patient Days by Service	1,444,962	1,445,826
Newborn Births	20,993	20,779
Newborn Patient Days	39,034	36,202
Outpatient Visits (Includes Surgical and ER Visits)	7,156,424	7,059,791
Surgical Visits - Outpatient	105,145	105,359
Emergency Room (ER) Visits	790,686	669,155
Full Time Equivalent Employees	134,251	134,825
Total Available Beds	26,349	27,843
Total Available Beds Excluding Bassinets	25,177	26,635